Exenatide in combination therapy: small study, big market, and many unanswered questions.
Malozowski
Saul
S
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D012107:Research Design / Q000592:standards*; D045162:Thiazolidinediones / Q000627:therapeutic use; D014688:Venoms / Q000009:adverse effects / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D010455:Peptides; D045162:Thiazolidinediones; D014688:Venoms; D008687:Metformin; D000077270:Exenatide; C089946:2,4-thiazolidinedione